Now showing items 1-20 of 34

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      <h4>Background</h4>Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using ...
    • Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. 

      Clarke, NW; Ali, A; Ingleby, FC; Hoyle, A; Amos, CL; Attard, G; Brawley, CD; Calvert, J; Chowdhury, S; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gilbert, D; Gillessen, S; Jones, RJ; Langley, RE; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Parker, CC; Ritchie, AWS; Rush, H; Russell, JM; Brown, J; Beesley, S; Birtle, A; Capaldi, L; Gale, J; Gibbs, S; Lydon, A; Nikapota, A; Omlin, A; O'Sullivan, JM; Parikh, O; Protheroe, A; Rudman, S; Srihari, NN; Simms, M; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A; Sydes, MR; Parmar, MKB; James, ND (2019-12)
      <h4>Background</h4>STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      <h4>Background</h4>Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits ...
    • Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. 

      Blackledge, MD; Collins, DJ; Tunariu, N; Orton, MR; Padhani, AR; Leach, MO; Koh, D-M (2014-01)
      We describe our semi-automatic segmentation of whole-body diffusion-weighted MRI (WBDWI) using a Markov random field (MRF) model to derive tumor total diffusion volume (tDV) and associated global apparent diffusion coefficient ...
    • The challenge of targeting cancer stem cells to halt metastasis. 

      Agliano, A; Calvo, A; Box, C (2017-06)
      Despite a continuing debate about the existence of cancer stem cells (CSCs), recent discoveries have provided further support for their existence and their roles in drug resistance, cancer recurrence and metastasis. CSC ...
    • Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. 

      Guckenberger, M; Lievens, Y; Bouma, AB; Collette, L; Dekker, A; deSouza, NM; Dingemans, A-MC; Fournier, B; Hurkmans, C; Lecouvet, FE; Meattini, I; Méndez Romero, A; Ricardi, U; Russell, NS; Schanne, DH; Scorsetti, M; Tombal, B; Verellen, D; Verfaillie, C; Ost, P (2020-01)
      Oligometastatic disease has been proposed as an intermediate state between localised and systemically metastasised disease. In the absence of randomised phase 3 trials, early clinical studies show improved survival when ...
    • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 

      Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; Perez-Lopez, R; Nava Rodrigues, D; Robinson, D; Omlin, A; Tunariu, N; Boysen, G; Porta, N; Flohr, P; Gillman, A; Figueiredo, I; Paulding, C; Seed, G; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, T; McGovern, U; Bianchini, D; Goodall, J; Zafeiriou, Z; Williamson, CT; Ferraldeschi, R; Riisnaes, R; Ebbs, B; Fowler, G; Roda, D; Yuan, W; Wu, YM; Cao, X; Brough, R; Pemberton, H; A'Hern, R; Swain, A; Kunju, LP; Eeles, R; Attard, G; Lord, CJ; Ashworth, A; Rubin, MA; Knudsen, KE; Feng, FY; Chinnaiyan, AM; Hall, E; de Bono, JS
      Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to ...
    • Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer. 

      Tree, AC; Jones, K; Hafeez, S; Sharabiani, MTA; Harrington, KJ; Lalondrelle, S; Ahmed, M; Huddart, RA (2018-08)
      There is currently significant interest in the potential benefits of combining radiation and immune checkpoint blockade (ICB) to stimulate both regional and distant abscopal immune responses. In melanoma and lung cancer, ...
    • Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. 

      Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; O'Sullivan, H; Alaras, M; Kolinsky, M; Sumanasuriya, S; Sousa Fontes, M; Mateo, J; Perez Lopez, R; Tunariu, N; Fotiadis, N; Kumar, P; Tree, A; Van As, N; Khoo, V; Parker, C; Eeles, R; Thompson, A; Dearnaley, D; de Bono, JS (2017-10)
      <h4>Background</h4>The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) ...
    • Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. 

      Loriot, Y; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, R; Burgess, E; Fleming, M; Rezazadeh, A; Mellado, B; Varlamov, S; Joshi, M; Duran, I; Tagawa, ST; Zakharia, Y; Zhong, B; Stuyckens, K; Santiago-Walker, A; De Porre, P; O'Hagan, A; Avadhani, A; Siefker-Radtke, AO; BLC2001 Study Group (2019-07)
      <h4>Background</h4>Alterations in the gene encoding fibroblast growth factor receptor (<i>FGFR</i>) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a ...
    • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. 

      Van Cutsem, E; Cervantes, A; Adam, R; Sobrero, A; Van Krieken, JH; Aderka, D; Aranda Aguilar, E; Bardelli, A; Benson, A; Bodoky, G; Ciardiello, F; D'Hoore, A; Diaz-Rubio, E; Douillard, J-Y; Ducreux, M; Falcone, A; Grothey, A; Gruenberger, T; Haustermans, K; Heinemann, V; Hoff, P; Köhne, C-H; Labianca, R; Laurent-Puig, P; Ma, B; Maughan, T; Muro, K; Normanno, N; Österlund, P; Oyen, WJG; Papamichael, D; Pentheroudakis, G; Pfeiffer, P; Price, TJ; Punt, C; Ricke, J; Roth, A; Salazar, R; Scheithauer, W; Schmoll, HJ; Tabernero, J; Taïeb, J; Tejpar, S; Wasan, H; Yoshino, T; Zaanan, A; Arnold, D (2016-08)
      Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved ...
    • Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. 

      Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; Bloomfield, DJ; Chan, C; Churn, M; Cleator, S; Coles, CE; Goodman, A; Harnett, A; Hopwood, P; Kirby, AM; Kirwan, CC; Morris, C; Nabi, Z; Sawyer, E; Somaiah, N; Stones, L; Syndikus, I; Bliss, JM; Yarnold, JR; FAST-Forward Trial Management Group (2020-05)
      <h4>Background</h4>We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international ...
    • <i>In Vivo</i> Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. 

      Yogev, O; Almeida, GS; Barker, KT; George, SL; Kwok, C; Campbell, J; Zarowiecki, M; Kleftogiannis, D; Smith, LM; Hallsworth, A; Berry, P; Möcklinghoff, T; Webber, HT; Danielson, LS; Buttery, B; Calton, EA; da Costa, BM; Poon, E; Jamin, Y; Lise, S; Veal, GJ; Sebire, N; Robinson, SP; Anderson, J; Chesler, L (2019-10)
      Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional treatment. In part, a lack of natively metastatic, chemoresistant <i>in vivo</i> models has limited our insight into the ...
    • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. 

      Pritchard, CC; Mateo, J; Walsh, MF; De Sarkar, N; Abida, W; Beltran, H; Garofalo, A; Gulati, R; Carreira, S; Eeles, R; Elemento, O; Rubin, MA; Robinson, D; Lonigro, R; Hussain, M; Chinnaiyan, A; Vinson, J; Filipenko, J; Garraway, L; Taplin, M-E; AlDubayan, S; Han, GC; Beightol, M; Morrissey, C; Nghiem, B; Cheng, HH; Montgomery, B; Walsh, T; Casadei, S; Berger, M; Zhang, L; Zehir, A; Vijai, J; Scher, HI; Sawyers, C; Schultz, N; Kantoff, PW; Solit, D; Robson, M; Van Allen, EM; Offit, K; de Bono, J; Nelson, PS (2016-08)
      <h4>Background</h4>Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with ...
    • Major Amputations for Extremity Soft-Tissue Sarcoma. 

      Smith, HG; Thomas, JM; Smith, MJF; Hayes, AJ; Strauss, DC (2018-02)
      <h4>Introduction</h4>With modern techniques facilitating limb conservation, amputation for extremity soft-tissue sarcoma (ESTS) is now rare. We sought to determine the indications and outcomes following major amputation ...
    • Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation. 

      Brand, D; Parker, C (2018-04)
      In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay ...
    • Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. 

      Ferris, RL; Licitra, L; Fayette, J; Even, C; Blumenschein, G; Harrington, KJ; Guigay, J; Vokes, EE; Saba, NF; Haddad, R; Ramkumar, S; Russell, J; Brossart, P; Tahara, M; Colevas, AD; Concha-Benavente, F; Lynch, M; Li, L; Gillison, ML (2019-09)
      <h4>Purpose</h4>Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or ...
    • Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. 

      Saba, NF; Blumenschein, G; Guigay, J; Licitra, L; Fayette, J; Harrington, KJ; Kiyota, N; Gillison, ML; Ferris, RL; Jayaprakash, V; Li, L; Brossart, P (2019-09)
      <h4>Objectives</h4>Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. ...
    • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Docampo, LCI; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Lynch, M; Jayaprakash, V; Li, L; Gillison, ML (2018-06)
      OBJECTIVES:We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory ...
    • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. 

      Vlachogiannis, G; Hedayat, S; Vatsiou, A; Jamin, Y; Fernández-Mateos, J; Khan, K; Lampis, A; Eason, K; Huntingford, I; Burke, R; Rata, M; Koh, D-M; Tunariu, N; Collins, D; Hulkki-Wilson, S; Ragulan, C; Spiteri, I; Moorcraft, SY; Chau, I; Rao, S; Watkins, D; Fotiadis, N; Bali, M; Darvish-Damavandi, M; Lote, H; Eltahir, Z; Smyth, EC; Begum, R; Clarke, PA; Hahne, JC; Dowsett, M; de Bono, J; Workman, P; Sadanandam, A; Fassan, M; Sansom, OJ; Eccles, S; Starling, N; Braconi, C; Sottoriva, A; Robinson, SP; Cunningham, D; Valeri, N (2018-02)
      Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from ...